New Horizon Health
Researches and develops technology for early-stage cancer screening.
loading funding rounds…
Legend Capital(exited)
SB China Capital(exited)
VMS Investment Group(exited)
OmniScience(exited)
Exome Asset Management(exited)
Rock Springs Capital(exited)
OrbiMed(exited)
Lilly Asia Ventures(exited)
Cormorant Asset Management(exited)
Octagon Capital Partners(exited)
Acorn Pacific Ventures(exited)
Qiming Venture Partners(exited)
VMS Asset Management(exited)
| CNY | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 21 % | 202 % | 260 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (153 %) | (1064 %) | (1431 %) | (4 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (183 %) | (1118 %) | (1450 %) | (10 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 45 % | 36 % | 28 % | 12 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
ACQUISITION by Onconetix Dec 2023